DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as the first TROP2-directed antibody-drug conjugate for first-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for…
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of…
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology Blank Bio, an applied AI research lab training foundation models for RNA, announced the closing of a $7.2 million seed financing and…
Atrandi Biosciences Expands Leadership Team to Accelerate Global Adoption of Capsule-Based Single-Cell Technology Atrandi Biosciences, a life science tools company pioneering Semi-Permeable Capsule (SPC) technology for single-cell and multiomics research, today announced the appointment of Sam Ropp, PhD, as Chief…
AVL Hosts Virtual Salon Suite Exploring How IVF Research Inspired a New Era of Science-Backed Skincare AV Laboratories, the science-backed skincare brand redefining the intersection of science, skincare, and longevity, will host an exclusive virtual salon suite on Thursday, May 21,…
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic…
Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC) Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced significant updates to two mission-driven initiatives:…
Osmo, the Olfactory Technology Company, Opens New Headquarters and Manufacturing Facility in Elizabeth, New Jersey Osmo, the olfactory technology company, marked the opening of its 60,000-square-foot manufacturing facility in Elizabeth, New Jersey. The facility, where Osmo will expand the commercialization…
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active…
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company…
Chemical Reduction Solutions LLC Expands Partnership with Simoniz USA Inc. to Exclusively Commercialize Nanobubble Technology in the Car Wash Industry Chemical Reduction Solutions LLC (“CRS”), a developer of hydrodynamic cavitation-based nanobubble technology, today announced an expanded partnership with Simoniz USA…
TRUQAP® (capivasertib)recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy…